| 张树红,康淑芳,付秀丽,聂鑫鑫,梁 军.基于炎症免疫调节探讨宫炎平胶囊联合左氧氟沙星、奥硝唑治疗慢性盆腔炎的疗效及其作用机制[J].现代生物医学进展英文版,2024,(18):3480-3484. |
| 基于炎症免疫调节探讨宫炎平胶囊联合左氧氟沙星、奥硝唑治疗慢性盆腔炎的疗效及其作用机制 |
| Explore the Therapeutic Efficacy and Mechanism of Gongyanping Capsule Combined with Levofloxacin and Ornidazole in the Treatment of Chronic Pelvic Inflammatory Disease Based on Inflammatory Immune Regulation |
| Received:December 12, 2023 Revised:January 08, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.18.015 |
| 中文关键词: 宫炎平胶囊 左氧氟沙星 奥硝唑 慢性盆腔炎 疗效 作用机制 |
| 英文关键词: Gong Yanping Capsules Levofloxacin Ornidazole Chronic pelvic inflammatory disease Efficacy Mechanism |
| 基金项目:山东省医药卫生科技计划基金项目（2021JD81） |
|
| Hits: 62 |
| Download times: 37 |
| 中文摘要: |
| 摘要 目的：基于炎症免疫调节探讨宫炎平胶囊联合左氧氟沙星、奥硝唑治疗慢性盆腔炎（CPID）的疗效及其作用机制，旨在为CPID患者的治疗提供临床指导。方法：选取2021年3月至2023年3月本院收治的CPID患者共计96例，以随机数字表法分成研究组（n=48）和对照组（n=48），对照组给予左氧氟沙星、奥硝唑治疗，研究组给予宫炎平胶囊联合左氧氟沙星、奥硝唑治疗，比较两组临床疗效、临床症状改善时间、月经量、盆腔炎性包块直径、盆腔积液深度、炎症反应、免疫功能、不良反应发生率、复发率。结果：研究组治疗总有效率为95.83%（46/48），较对照组的79.17%（38/48）更高（P<0.05）；研究组临床症状改善时间较对照组更短（P<0.05），月经量更少（P<0.05）；两组治疗后盆腔炎性包块直径缩短（P<0.05），盆腔积液深度降低（P<0.05），研究组盆腔炎性包块直径较对照组更短（P<0.05），盆腔积液深度更低（P<0.05）；两组治疗后白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）、单核细胞趋化蛋白-1（MCP-1）、干扰素-γ（IFN-γ）水平下降（P<0.05），研究组较对照组更低（P<0.05）；两组治疗后CD4+、CD4+/CD8+升高（P<0.05），CD8+、免疫球蛋白A（IgA）、免疫球蛋白G（IgG）、免疫球蛋白M（IgM）下降（P<0.05），研究组CD4+、CD4+/CD8+较对照组更高（P<0.05），CD8+、IgA、IgM、IgG更低（P<0.05）；两组不良反应发生率比较无差异（P>0.05）；研究组复发率为2.08%（1/48），较对照组的16.67%（8/48）更低（P<0.05）。结论：宫炎平胶囊与左氧氟沙星、奥硝唑联合治疗CPID患者的临床疗效较高，能够加快临床症状缓解，减少月经量，改善盆腔炎性包块直径和盆腔积液深度，且不会不良反应增加，避免疾病复发，其作用机制可能与调节患者炎症免疫功能有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy and mechanism of Gongyanping capsule combined with levofloxacin and ornidazole in the treatment of chronic pelvic inflammatory disease (CPID) based on inflammatory immune regulation, in order to provide clinical guidance for the treatment of CPID patients. Methods: A total of 96 CPID patients admitted to our hospital from March 2021 to March 2023 were selected and divided into study group(n=48) and control group(n=48) by random number table method. The control group was treated with levofloxacin and ornidazole, and the study group was treated with Gongyanping capsule combined with levofloxacin and Ornidazole. The clinical efficacy, clinical symptom improvement time, menstrual volume, pelvic inflammatory mass diameter, pelvic effusion depth, inflammatory response, immune function, incidence rate of adverse reactions and recurrence rate were compared between the two groups. Results: The total effective rate of the study group was 95.83% (46/48), higher than that of the control group (79.17% (38/48) (P<0.05). The clinical symptom improvement time, in the study group was shorter than that in the control group (P<0.05), and the menstrual volume was less(P<0.05). After treatment, the pelvic inflammatory mass diameter was shortened (P<0.05) and the pelvic effusion depth was decreased (P<0.05), and the pelvic inflammatory mass diameter in the study group was shorter than that in the control group (P<0.05), and the pelvic effusion depth was lower(P<0.05). After treatment, the levels of interleukin-1β (IL-1β), tumor necrosis factor-α(TNF-α), monocyte chemoattractant protein-1(MCP-1) and interferon-γ(IFN-γ) in two groups were decreased(P<0.05), and the levels in the study group were lower than those in the control group(P<0.05). After treatment, CD4+, CD4+/CD8+ increased in both groups (P<0.05), and CD8+, immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) decreased (P<0.05), and CD4+, CD4+/CD8++ in the study group were higher than those in the control group(P<0.05). CD8+, IgA, IgM and IgG were lower(P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05). The recurrence rate of the study group was 2.08%(1/48), which was lower than that 16.67%(8/48) of the control group(P<0.05). Conclusion: Gongyanping capsule combined with levofloxacin and Ornidazole has high clinical efficacy in the treatment of CPID patients, which can accelerate the relief of clinical symptoms, reduce menstrual volume, improve the pelvic inflammatory mass diameter and pelvic effusion depth, without increasing adverse reactions and avoiding disease recurrence, the mechanism of action may be related to the regulation of inflammatory and immune function of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
